Clinical trialNCT01074008CompletedPhase 2Interventional

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

SponsorAbbVie (prior sponsor, Abbott)Enrollment74Chronic Hepatitis C InfectionHCVHepatitis CHepatitis C Genotype 1

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Daniel Cohen
AbbVie
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Puerto Rico

Site Reference Id/investigator# 23363
Ponce, Puerto Rico

United States

Site Reference Id/investigator# 23392
Phoenix, Arizona, United States
Site Reference Id/investigator# 23370
Anaheim, California, United States
Site Reference Id/investigator# 23387
La Jolla, California, United States
Site Reference Id/investigator# 23388
Los Angeles, California, United States
Site Reference Id/investigator# 23371
Aurora, Colorado, United States
Site Reference Id/investigator# 23369
Orlando, Florida, United States
Site Reference Id/investigator# 26362
Orlando, Florida, United States
Site Reference Id/investigator# 23373
Chicago, Illinois, United States
Site Reference Id/investigator# 24908
Chicago, Illinois, United States
Site Reference Id/investigator# 23381
Indianapolis, Indiana, United States
Site Reference Id/investigator# 23372
Baton Rouge, Louisiana, United States
Site Reference Id/investigator# 24710
New Orleans, Louisiana, United States
Site Reference Id/investigator# 23391
Baltimore, Maryland, United States
Site Reference Id/investigator# 23377
Detroit, Michigan, United States
Site Reference Id/investigator# 24909
Saint Paul, Minnesota, United States
Site Reference Id/investigator# 23379
New York, New York, United States
Site Reference Id/investigator# 35842
New York, New York, United States
Site Reference Id/investigator# 23375
Chapel Hill, North Carolina, United States
Site Reference Id/investigator# 23385
Durham, North Carolina, United States
Site Reference Id/investigator# 23376
Dallas, Texas, United States
Site Reference Id/investigator# 24891
Houston, Texas, United States
Site Reference Id/investigator# 23382
San Antonio, Texas, United States
Site Reference Id/investigator# 24715
Salt Lake City, Utah, United States
Site Reference Id/investigator# 25463
Seattle, Washington, United States
Site Reference Id/investigator# 23383
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ABT-072ABT-333ABT-450Peginterferon alpha-2aRibavirin →Ritonavir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2010
Primary completion: 30 Jun 2011
Completion: 31 Jan 2012
Last update posted: 8 Jan 2015
Registered enrollment: 74
Registry id: NCT01074008

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.